Prof. Ge Lou 娄阁
Chief Physician, Professor
Department of Gynecology, Harbin Medical University Cancer Hospital, Harbin
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Diagnosis and comprehensive treatment of cervical, ovarian, endometrial, vulvar cancers, trophoblastic tumors, cervical diseases, and uterine fibroids. Specializes in gynecologic laparoscopy, hysteroscopy, and standardized malignant tumor therapy.
Dr. Lou is a Professor and Chief of Gynecology with over 20 years of experience. Graduated from Harbin Medical University in 1989; completed training at Georgetown University Medical Center (1999–2000). Holds a postdoctoral degree and supervises doctoral students. Has led 14 research projects and published 88 papers, including 2 SCI-indexed articles.
Professional roles
- Chair, Gynecologic Oncology Professional Committee, China Anti-Cancer Association Heilongjiang Branch
- Vice Chair, Gynecologic Oncology Branch, Chinese Medical Association
- Member, Gynecologic Oncology Professional Committee, China Anti-Cancer Association
- Member, International Federation of Gynecology and Obstetrics (FIGO)
Name order: in Chinese the family name comes first (Lou Ge). Papers usually list the name as Ge Lou or Lou G.
Selected publications
89 papers on PubMed matched by name and affiliation; 34 as first or senior author since 2016. Most recent first- or senior-author papers:
- Cell Signal, 2026 (senior author): Epitranscriptomic stabilization of PGRMC1 by the METTL3-IGF2BP1 axis promotes ovarian cancer progression. PubMed 42777928
- Curr Pharm Biotechnol, 2026 (senior author): CDS1 in Pan-Cancer: A Systematic Multidimensional Evaluation. PubMed 42576572
- Biochim Biophys Acta Gen Subj, 2025 (senior author): USP33-mediated stabilization of c-Myc drives glycolytic reprogramming and promotes ovarian cancer progression. PubMed 40532745
- Cancer Cell Int, 2025 (senior author): Characterization of G2/M checkpoint classifier for personalized treatment in uterine corpus endometrial carcinoma. PubMed 39920729
- Oncol Lett, 2025 (senior author): Olaparib promotes FABP4 expression and reduces antitumor effect in ovarian cancer cells with a BRCA1 mutation. PubMed 39619421
- Gene, 2025 (senior author): Clinical and prognostic significance of FBXL6 expression in ovarian cancer. PubMed 39368786
- J Transl Med, 2024 (senior author): m(6)A methylation-mediated regulation of LncRNA MEG3 suppresses ovarian cancer progression through miR-885-5p and the VASH1 pathway. PubMed 38281945
- Cancer Biol Ther, 2023 (senior author): Revealing the inhibitory effect of VASH1 on ovarian cancer from multiple perspectives. PubMed 38010374
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that the papers match this doctor's specialty; this check is automatic.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion